China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January ...

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic Alzheimer’s ...

The approval of Kisunla in China is based on a press release statement from Eli Lilly and Company and offers a new avenue for addressing the challenges of Alzheimer's disease in a population with ...